IMDX - Insight Molecular Diagnostics Inc

NYSE * Health Care * Life Sciences Tools & Services

$3.00

$-0.17 (-5.36%)

About Insight Molecular Diagnostics Inc

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

IMDX Key Statistics

Market Cap

$101.97M

0

P/B Ratio

196.27

EPS

$-1.65

Revenue Growth

-0.2%

Employees

55

How IMDX Compares to Peers

IMDX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 1

Margin Rank

N/A

of 1

Growth Rank

#2

of 2

Size Rank

#2

of 2

CompanyP/EGrowthCompare
IMDXN/A-0%-
AMZN33.40%vs AMZN

Insight Molecular Diagnostics Inc Company Information

Headquarters
California; U.S.A
Website
imdxinc.com
Sector
Health Care
Industry
Life Sciences Tools & Services
Data Updated:
Ready to invest in IMDX?

Commission-free trading available. Affiliate links.

IMDX Lician Score

10% confidence
6.0/10
Good

IMDX has a Lician Score of 6/10 (Good). Strengths: Growth.

value

5.0

growth

8.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates IMDXacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

IMDX Financial Snowflake

5-axis analysis across key investment dimensions

5.6/10

Neutral

35810Value5.0Growth8.0Quality5.0Momentum5.0Safety5.05.6/10
5.0

Value

8.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for IMDX